<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1073">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04358614</url>
  </required_header>
  <id_info>
    <org_study_id>HPrato-4</org_study_id>
    <nct_id>NCT04358614</nct_id>
  </id_info>
  <brief_title>Baricitinib Therapy in COVID-19</brief_title>
  <official_title>Baricitinib Therapy in COVID-19: A Pilot Study on Safety and Clinical Impact</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fabrizio Cantini</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital of Prato</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective study on the efficacy of baricitinib in 12 COVID-19 patients with moderate
      pneumonia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Baricitinib, an anti-Janus kinase inhibitor (anti-JAK) acting against JAK1 and JAK2 that
      inhibits JAK1- and JAK2-mediated cytokine release, was recently described using
      BenevolentAI's proprietary artificial intelligence-derived knowledge graph, as an agent that
      reduces the endocytosis into target cells, and to inhibit the entry. Based on its potential
      action on inhibition of SARS-CoV-2 entry, and on its known effects on reduction of cytokine
      release, baricitinib therapy was proposed in patients with moderate pneumonia to explore: the
      safety of this drug combined with antiviral (lopinavir-ritonavir) in COVID-19; as second
      outcome, to evaluate the impact of baricitinib in terms of clinical, laboratory, respiratory
      parameters, and reduction of ICU admission.

      Baricitinib was combined with antivirals because it does not interact with them due to its
      prevalent renal elimination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 16, 2020</start_date>
  <completion_date type="Actual">April 7, 2020</completion_date>
  <primary_completion_date type="Actual">April 5, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Baricitinib treated patients compared with controls (previously COVID-19 receving standard therapy)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the safety of baricitinib combined with antiviral (lopinavir-ritonavir) in terms of serious or non-serious adverse events incidence rate.</measure>
    <time_frame>2 weeks</time_frame>
    <description>All adverse event recording</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the impact of baricitinib in terms of clinical, laboratory, respiratory parameters.</measure>
    <time_frame>2 weeks</time_frame>
    <description>The percentage of patients improving the clinical and respiratory parameters compared with controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU admission rate</measure>
    <time_frame>2 weeks</time_frame>
    <description>The percentage of ICU admission in baricitinib group as compared with controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discharge rate.</measure>
    <time_frame>2 weeks</time_frame>
    <description>The percentage of discharged in baricitinib group as compared with controls.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>COVID</condition>
  <condition>Pneumonia</condition>
  <arm_group>
    <arm_group_label>Case patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Consecutive patients with COVID moderate pneumonia treated with baricitinib tablets 4 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Consecutive patients with COVID moderate pneumonia treated with standard therapy before the date of the first baricitinib-treated patient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baricitinib 4 MG Oral Tablet</intervention_name>
    <description>Baricitinib+antiviral therapy administration for 2 weeks</description>
    <arm_group_label>Case patients</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
    <other_name>Lopinavir/Ritonavir tablets 250 mg/bid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  SARS-Co-V2 positivitity to the nasal-swab by reverse-transcriptase-polymerase chain-
             reaction (RT-PCR) assay tested by the local diagnostic laboratory

          -  Age &gt;18 and &lt;85 years

          -  Presence of at least 3 of the following symptoms as present fever, cough, myalgia,
             fatigue.

          -  Presence of radiological findings of pneumonia assessed by chest radiograph, computed
             tomography, or pulmonary ultrasound.

          -  Peripheral capillary oxygen saturation (SpO2) &gt; 92% on room air at screening

          -  PaO2/FiO2 &gt;100-300 mmHg at arterial blood gas analysis.

        Exclusion Criteria:

          -  Age &lt; 18 and &gt;85

          -  History of thrombophlebitis

          -  Latent tuberculosis infection (based on the positivity to QuantiFERON Plus positivity,
             Qiagen, Germany)

          -  Pregnancy and lactation

          -  History of malignancies over the previous 5 years, current diagnosis of malignancy

          -  Inability or unwillingness to sign a written consent.

          -  Transaminases values 4-fold higher than the upper normal limit.

          -  HBV and HCV positivity.

          -  Current Herpes zoster infection.

          -  Evidence of concomitant bacterial infections.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fabrizio Cantini</name>
      <address>
        <city>Prato</city>
        <state>Tuscany</state>
        <zip>59100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Conner SD, Schmid SL. Identification of an adaptor-associated kinase, AAK1, as a regulator of clathrin-mediated endocytosis. J Cell Biol. 2002 Mar 4;156(5):921-9. Epub 2002 Mar 4.</citation>
    <PMID>11877461</PMID>
  </reference>
  <reference>
    <citation>Ferner RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19. BMJ. 2020 Apr 8;369:m1432. doi: 10.1136/bmj.m1432.</citation>
    <PMID>32269046</PMID>
  </reference>
  <reference>
    <citation>Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, Rawling M, Savory E, Stebbing J. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020 Feb 15;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4. Epub 2020 Feb 4. Erratum in: Lancet. 2020 Jun 20;395(10241):1906.</citation>
    <PMID>32032529</PMID>
  </reference>
  <reference>
    <citation>Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, Richardson P. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020 Apr;20(4):400-402. doi: 10.1016/S1473-3099(20)30132-8. Epub 2020 Feb 27.</citation>
    <PMID>32113509</PMID>
  </reference>
  <reference>
    <citation>Subbe CP, Kruger M, Rutherford P, Gemmel L. Validation of a modified Early Warning Score in medical admissions. QJM. 2001 Oct;94(10):521-6.</citation>
    <PMID>11588210</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 19, 2020</study_first_submitted>
  <study_first_submitted_qc>April 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital of Prato</investigator_affiliation>
    <investigator_full_name>Fabrizio Cantini</investigator_full_name>
    <investigator_title>MD, Head of Rheumatology Department, Principal investigator</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>BARICITINIB</keyword>
  <keyword>MODERATE DISEASE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

